To this end, we hypothesized that utilizing advantages of cancer cell specificity of anti-PLAC1 antibodies and cytotoxic activity of a chemically supertoxic agent could be considered an ideal approach for generation of an antibody drug conjugate (ADC) platform for targeted immunotherapy of PCa. This evidence concerns the gene PLAC1 and cancer.